It adds to other variables recently suggested to affect the interaction of GLP-1R agonists with depression, which include existing and treated diabetes or obesity, age, duration of treatment, whether comparisons are made to control groups receiving placebo or other antiobesity medications, and whether patients with preexisting psychiatric diagnosis are included. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.